Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide inAcute Heart Failure with Reduced or Preserved Ejection Fraction: Results fromthe Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSEAHF)

摘要

BACKGROUNDThe Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial found that as compared to placebo, neither low-dose dopamine (2 ug/kg/min) nor low-dose nesiritide (0.005 µg/kg/min without bolus) enhanced decongestion or preserved renal function in AHF patients with renal dysfunction. However, there may be differential responses to vasoactive agents in AHF patients with reduced versus preserved ejection fraction (EF). This post-hoc analysis examined potential interaction between treatment effect and EF group (EF ≤ 40% vs > 40%) on the ROSE AHF endpoints.